These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10915756)

  • 1. Maintenance interferon for chronic hepatitis C: more issues than answers?
    Everson GT
    Hepatology; 2000 Aug; 32(2):436-8. PubMed ID: 10915756
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer.
    Ikeda K; Arase Y; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Tsubota A; Chayama K; Murashima N; Kumada H
    Hepatology; 2000 Aug; 32(2):228-32. PubMed ID: 10915728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summaries for patients. Does interferon-alpha prevent recurrence of malignant tumors in patients with hepatitis C - related liver cancer?
    Ann Intern Med; 2001 May; 134(10):S-7. PubMed ID: 11357861
    [No Abstract]   [Full Text] [Related]  

  • 4. [The prophylaxis of hepatocellular carcinoma by interferon-alpha in virus-induced cirrhosis].
    Merle P; Zoulim F; Vitvitski L; Trépo C
    Gastroenterol Clin Biol; 2000 Dec; 24(12):1166-76. PubMed ID: 11173729
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-term prognosis of chronic hepatitis C--special reference to interferon therapy].
    Arakawa Y
    Nihon Naika Gakkai Zasshi; 1998 Mar; 87(3):480-5. PubMed ID: 9577579
    [No Abstract]   [Full Text] [Related]  

  • 6. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of hepatocellular carcinoma after sustained response to interferon therapy: how long should sustained responders with risk factors be followed?
    Kasahara A
    J Gastroenterol; 2005 Feb; 40(2):220-2. PubMed ID: 15770412
    [No Abstract]   [Full Text] [Related]  

  • 8. Interferon: benefit beyond hepatitis therapy?
    Mallat DB; El-Serag HB
    Am J Gastroenterol; 2001 Dec; 96(12):3435-6. PubMed ID: 11774964
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatocellular carcinoma and interferon therapy in HCV compensated cirrhosis: evaluation in relation to virological response.
    Testino G; Icardi G
    Hepatogastroenterology; 2005; 52(63):4 p preceding table of contents. PubMed ID: 15966175
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy.
    Kubo S; Nishiguchi S; Hirohashi K; Tanaka H; Shuto T; Kinoshita H
    Br J Surg; 2002 Apr; 89(4):418-22. PubMed ID: 11952580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
    Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
    Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
    Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
    Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic hepatitis C: what to do if the first treatment failed?].
    Asselah T
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B50-9. PubMed ID: 12180309
    [No Abstract]   [Full Text] [Related]  

  • 14. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
    Basso M; Torre F; Picciotto A
    Cancer; 2005 Jun; 103(12):2654-5; author reply 2655. PubMed ID: 15884032
    [No Abstract]   [Full Text] [Related]  

  • 15. [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
    Schott E; Bergk A; Berg T
    Z Gastroenterol; 2008 Jan; 46(1):69-80. PubMed ID: 18188819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
    Makiyama A; Itoh Y; Kasahara A; Imai Y; Kawata S; Yoshioka K; Tsubouchi H; Kiyosawa K; Kakumu S; Okita K; Hayashi N; Okanoue T
    Cancer; 2004 Oct; 101(7):1616-22. PubMed ID: 15378504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of hepatocellular carcinoma.
    Craxì A; Cammà C
    Clin Liver Dis; 2005 May; 9(2):329-46, viii. PubMed ID: 15831277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
    Soga K; Shibasaki K; Aoyagi Y
    Hepatogastroenterology; 2005; 52(64):1154-8. PubMed ID: 16001651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hepatitis C virus-related cirrhosis].
    Bronowicki JP
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B220-4. PubMed ID: 12180292
    [No Abstract]   [Full Text] [Related]  

  • 20. Histological and nonhistological criteria in the evaluation of liver involvement in chronic hepatitis C.
    Mateescu RB; Rimbaş M; Stăniceanu F; Zurac S; Dragomir P; Voiosu MR; Tătaru M; Zota M; Bucurică S
    Rom J Intern Med; 2006; 44(2):117-30. PubMed ID: 17236293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.